Psychedelic Science Newsletter
Issue #16December 22, 20257 studies

Traumatized rats begin to heal on Ayahuasca — plus, psilocybin for end-of-life depression and anxiety

This week brought fascinating insights into how psychedelics rewire the brain—from rats conquering trauma-like memories with ayahuasca to the discovery of ketamine's hidden serotonin mechanism.

🐭 Rats Beat Trauma-Like Memories With Ayahuasca

  • Male and female rats given ayahuasca (containing 0.3 mg/kg DMT) showed enhanced extinction of fear memories that mimicked trauma-like characteristics—including overgeneralized fear and resistance to normal extinction training

  • The psychedelic brew worked by boosting brain-derived neurotrophic factor (BDNF) signaling in the infralimbic cortex, a brain region critical for fear extinction

  • When researchers blocked BDNF or its receptor TrkB in this brain area, ayahuasca lost its fear-busting effects entirely

Why it matters: This provides a specific biological mechanism for how psychedelics might help with PTSD-like conditions—by enhancing the brain's natural ability to form new, safer memories that override traumatic ones.

Key Findings

🧬 Ketamine's Hidden Serotonin Pathway Revealed

  • Ketamine blocks both NMDA receptors (already known) and serotonin transporters (SERT), elevating brain serotonin levels alongside its glutamate effects

  • Cryo-electron microscopy at 3.2 Å resolution showed ketamine binding directly to SERT's central site

  • This dual action activates specific VIP-expressing interneurons that are essential for ketamine's rapid antidepressant effects—blocking these neurons eliminates the benefits

💡 This dual mechanism may explain why ketamine works so much faster than traditional antidepressants that only target serotonin.
🥉 Top 5% journal 🔗 National science review Journal Article 🗓️ Dec 18

🔬 Psilocybin Cuts Depression by 79% in Terminal Patients

  • Across 6 studies with 74 participants (ages 22-75) facing end-of-life situations, psilocybin-assisted therapy produced 57-79% of patients achieving ≥50% reduction in depression and anxiety symptoms

  • Improvements lasted 6-8 months in most trials, with one follow-up showing benefits persisting up to 4.5 years

  • Side effects were mild and temporary (nausea, vomiting, brief blood pressure increases) with no serious adverse events

💡 These sustained improvements suggest psilocybin could transform end-of-life psychiatric care where traditional treatments often fall short.
🎖️ Top 10% journal 🔗 Palliative Medicine Review 🗓️ Dec 18

🎯 LSD Creates Global Brain Sync Through Sensory Suppression

  • LSD enhanced global brain synchrony by suppressing sensorimotor cortices while boosting transmodal brain regions, creating a more unified but less modular brain state

  • This "attractor state" recruited transitions from cognitive control networks and showed higher occurrence probability during the psychedelic experience

  • The drug converged excitatory/inhibitory balance across different brain hierarchies, potentially explaining both hallucinations and therapeutic effects on rigid thought patterns

💡 This global rebalancing may explain why LSD can break up entrenched mental patterns while creating altered perceptions.
🎖️ Top 10% journal 🔗 PLoS computational biology Journal Article 🗓️ Dec 15

🧪 Trauma Patients Get 6-Month PTSD Relief From Ketamine

  • 44 severely injured patients (Injury Severity Score ≥15) who received ketamine infusions for acute pain showed significantly less anxiety and PTSD symptoms at 3 and 6 months compared to placebo

  • The effect was strongest for re-experiencing symptoms (flashbacks, intrusive memories)—a core component of PTSD

  • This suggests ketamine given during the acute trauma period may prevent chronic PTSD development

💡 Early ketamine treatment could offer a preventive intervention for PTSD in trauma centers, potentially stopping the disorder before it becomes chronic.
Top 20% journal 🔗 Journal of Trauma and Acute Care Surgery Journal Article 🗓️ Dec 19

🔬 Psychedelic vs Meditation Experiences: Intensity Matters

  • Natural language processing of 197 experience reports (134 psychedelic, 63 meditation) found highly similar semantic content between the two types of transformative experiences

  • Both groups expressed positive emotions on average, but psychedelic reports showed significantly higher emotional intensity—more extreme positive and negative sentiments compared to more neutral meditation experiences

  • The content was remarkably similar, suggesting these practices may access similar psychological territories through different routes

💡 Emotional intensity, rather than content, may be the key distinguishing factor between psychedelic and meditative transformative experiences.
Top 20% journal 🔗 Scientific reports Comparative Study 🗓️ Dec 16

🧬 Female Rats Show Estrus-Dependent Ketamine Sensitization

  • Female rats developed behavioral sensitization to ketamine's locomotor effects, occurring more rapidly during proestrus than diestrus phases, while male rats showed no sensitization

  • RNA sequencing revealed more gene expression changes in D1 dopamine receptor neurons of proestrus females, particularly in transcription regulation and epitranscriptional modification pathways

  • These changes occurred in a drug-free state, suggesting lasting molecular adaptations linked to ketamine's behavioral effects

💡 Hormonal cycles may influence both ketamine's therapeutic effects and addiction potential, pointing to the need for sex-specific treatment protocols.
Top 20% journal 🔗 eNeuro Journal Article 🗓️ Dec 17

Implications

This week's research reveals psychedelics work through remarkably specific biological pathways—from ayahuasca's BDNF-dependent fear extinction to ketamine's dual serotonin-glutamate action. The findings suggest these treatments could be optimized by understanding individual factors like hormonal status and specific neural targets, potentially leading to more precise psychiatric interventions.

Studies in this issue

Primary sources used for this newsletter.

  1. Ayahuasca's effect on traumatic fear memories depends on brain growth factors in the thinking and decision-making area in rats
    main storyEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2025-12-18PMID 41411685
  2. Changes in brain balance of excitation and inhibition by LSD increase overall brain synchrony
    key findingPLoS computational biology2025-12-15PMID 41397035
  3. Comparing reports of psychedelic and meditation experiences using language analysis
    key findingScientific reports2025-12-16PMID 41402442
  4. Ketamine treatment for acute traumatic pain linked to lower PTSD and anxiety symptoms 6 months after hospital discharge
    key findingThe journal of trauma and acute care surgery2025-12-19PMID 41417647
  5. Blocking serotonin transport and NMDA receptors together may cause ketamine’s fast antidepressant effects
    key findingNational science review2025-12-18PMID 41409708
  6. Safety and effectiveness of psilocybin therapy for people receiving palliative care
    key findingPalliative medicine2025-12-18PMID 41410211
  7. Estrous cycle affects cell-specific protein-making patterns after repeated ketamine in the rat reward system
    key findingeNeuro2025-12-17PMID 41407537

Continue reading

All Psychedelic Science issues